Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › N-acetylcysteine amide (NACA) and (2R,2R′)-3,3′ disulfanediyl bis(2-acetamidopropanamide) (diNACA) for the prevention and treatment of radiation pneumonitis and treatment of pulmonary function in Cystic Fibrosis

N-acetylcysteine amide (NACA) and (2R,2R′)-3,3′ disulfanediyl bis(2-acetamidopropanamide) (diNACA) for the prevention and treatment of radiation pneumonitis and treatment of pulmonary function in Cystic Fibrosis

US Patent 12245998 · Granted Mar 11, 2025

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

N-Acetylcysteine Amide (NACA) and (2R,2R′)-3,3′ disulfanediyl BIS(2-acetamidopro2025
Treatment of age-related macular degeneration, glaucoma, and diabetic retinopath2023
Methods of making deuterium-enriched N-acetylcysteine amide (d-NACA) and (2R, 2R2023
Method for preparation of n-acetyl cysteine amide and derivatives thereof2023
Method for preparation of N-acetyl cysteine amide and derivatives thereof2021
Method for preparation of N-acetyl cysteine amide and derivatives thereof2020
Method of treating middle ear infections2016
Method of treating middle ear infections2016
Method of treating middle ear infections2015
Method of treating middle ear infections2014
Olopatadine formulations for topical nasal administration2013
Olopatadine formulations for topical nasal administration2011